succinic acid Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2487 | 110-15-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851)
|
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| CHEBI has role | CHEBI:49201 | anti-ulcer drug |
| CHEBI has role | CHEBI:50733 | nutraceutical |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Iron deficiency anemia | indication | 87522002 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Primary hyperoxaluria | contraindication | 17901006 | DOID:2977 |
| Gastroenteritis | contraindication | 25374005 | DOID:2326 |
| Hemosiderosis | contraindication | 39011001 | DOID:12119 |
| Hemolytic anemia | contraindication | 61261009 | DOID:583 |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Hb SS disease | contraindication | 127040003 | DOID:10923 |
| Diverticular disease | contraindication | 397881000 | |
| Hemochromatosis | contraindication | 399187006 | DOID:2352 |
| Repeated Blood Transfusions | contraindication |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.81 | acidic |
| pKa2 | 5.28 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Egl nine homolog 1 | Enzyme | IC50 | 5.52 | CHEMBL | |||||
| Succinate receptor 1 | GPCR | AGONIST | EC50 | 4.70 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4028568 | VUID |
| N0000178335 | NUI |
| C0075429 | UMLSCUI |
| 60376006 | SNOMEDCT_US |
| NOCODE | MMSL |
| 4028568 | VANDF |
| 37255 | RXNORM |
| 002404 | NDDF |
| AB6MNQ6J6L | UNII |
| 1110 | PUBCHEM_CID |
| CHEBI:15741 | CHEBI |
| CHEMBL576 | ChEMBL_ID |
| DB00139 | DRUGBANK_ID |
| SIN | PDB_CHEM_ID |
| D019802 | MESH_DESCRIPTOR_UI |
| 3637 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| IROSPAN 24/6 | HUMAN PRESCRIPTION DRUG LABEL | 20 | 50967-126 | KIT | 150 mg | None | unapproved drug other | 9 sections |
| Viatrexx-Adipose | HUMAN PRESCRIPTION DRUG LABEL | 10 | 73069-024 | INJECTION | 31 [kp_C] | INTRAVENOUS | unapproved drug other | 11 sections |
| Viatrexx-Cellulite | HUMAN PRESCRIPTION DRUG LABEL | 10 | 73069-081 | INJECTION | 31 [kp_C] | INTRAVENOUS | unapproved drug other | 11 sections |
| Viatrexx-Facial | HUMAN PRESCRIPTION DRUG LABEL | 11 | 73069-164 | INJECTION | 31 [kp_C] | INTRAVENOUS | unapproved drug other | 11 sections |
| Viatrexx-Ki-UB | HUMAN PRESCRIPTION DRUG LABEL | 2 | 73069-277 | INJECTION | 31 [kp_C] | INTRAVENOUS | unapproved drug other | 11 sections |
| Viatrexx-Pigmentation | HUMAN PRESCRIPTION DRUG LABEL | 9 | 73069-410 | INJECTION | 31 [kp_C] | INTRAVENOUS | unapproved drug other | 11 sections |
| Niferex | HUMAN PRESCRIPTION DRUG LABEL | 5 | 75854-321 | TABLET | 50 mg | ORAL | unapproved drug other | 12 sections |